Naltrexone Hydrochloride | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Naltrexone Hydrochloride
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

PharmaCompass Sponsored Ads

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Naltrexone Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

70 API Suppliers, 9 USDMF, 7 CEP/COS, 2 EU WC, 7 KDMF, 52 NDC API, 18 Listed Suppliers, $ API Reference Price

70 API Suppliers
9 USDMF
7 CEP/COS
2 EU WC
7 KDMF
52 NDC API
18 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

30 Drugs in Development

30 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

47 FDF Dossiers, 23 FDA Orange Book, 14 Europe, 4 Canada, 2 South Africa, 4 Listed Dossiers

47 FDF Dossiers
23 FDA Orange Book
14 Europe
4 Canada
2 South Africa
4 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 90MG;8MG, CAPSULE, EXTENDED RELEASE;ORAL - 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 20MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 90MG;8MG
CAPSULE, EXTENDED RELEASE;ORAL - 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 20MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

3 Evonik, 1 SPI Pharma, 10 DKSH, 4 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 5 Kirsch Pharma, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 1 CD Formulation, 1 Clariant, 18 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 1 Finar, 10 Gangwal Chemicals, 8 Ideal Cures, 1 Ingredion Pharma Solutions, 23 Kerry, 2 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 10 Roquette, 12 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 3 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

59 Coating Systems & Additives, 38 Fillers, Diluents & Binders, 36 Controlled & Modified Release, 28 Thickeners and Stabilizers, 24 Granulation, 22 Direct Compression, 19 Solubilizers, 14 Parenteral, 14 Lubricants & Glidants, 14 Disintegrants & Superdisintegrants, 13 Topical, 12 Film Formers & Plasticizers, 11 Taste Masking, 9 Co-Processed Excipients, 9 Empty Capsules, 7 Emulsifying Agents, 7 Rheology Modifiers, 5 Surfactant & Foaming Agents, 5 API Stability Enhancers, 5 Coloring Agents, 4 Chewable & Orodispersible Aids, 4 Vegetarian Capsules

59 Coating Systems & Additives
38 Fillers, Diluents & Binders
36 Controlled & Modified Release
28 Thickeners and Stabilizers
24 Granulation
22 Direct Compression
19 Solubilizers
14 Parenteral
14 Lubricants & Glidants
14 Disintegrants & Superdisintegrants
13 Topical
12 Film Formers & Plasticizers
11 Taste Masking
9 Co-Processed Excipients
9 Empty Capsules
7 Emulsifying Agents
7 Rheology Modifiers
5 Surfactant & Foaming Agents
5 API Stability Enhancers
5 Coloring Agents
4 Chewable & Orodispersible Aids
4 Vegetarian Capsules

DIGITAL CONTENT

49 News #PharmaBuzz

49 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions, 17 Regulatory FDF Prices

12 US Medicaid Prescriptions
17 Regulatory FDF Prices

MARKET PLACE

16 APIs, 3 FDF Dossiers

16 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

85 US Patents, 4 Health Canada Patents

85 US Patents
4 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 7 Others

2 EDQM
7 Others

$ API Ref.Price (USD/KG) : 6,845 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Bausch Health, Canada Inc.

filter Patent Reset all filters

4 All

01 12522708

02 12668884

03 12668885

04 12932127

filter Product Reset all filters

4 All

01 4BUPROPION HYDROCHLORIDE | NALTREXONE HYDROCHLORIDE

filter Dosage Reset all filters

4 All

01 4TABLET (EXTENDED-RELEASE)

filter Exp Date Reset all filters

4 All

01 12024-04-21

02 22027-11-08

03 12034-12-04

Naltrexone Hydrochloride

Product Main Page

01

Bausch Health, Canada Inc.

Bupropion Hydrochloride, Naltrexone Hydrochloride

Peptide Process CMC

Not Confirmed

Bausch Health, Canada Inc.

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-04-21

Date Granted : 2013-05-28

Bupropion Hydrochloride, Naltrexone Hydrochloride

Brand Name : CONTRAVE

Patent Number : 2522708

Filing Date : 2004-04-21

Strength per Unit : 8mg / 90mg

Dosage Form : TABLET (EXTENDED-RELEASE)

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-04-21

Date Granted : 2013-05-28

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Bausch Health, Canada Inc.

Bupropion Hydrochloride, Naltrexone Hydrochloride

Peptide Process CMC

Not Confirmed

Bausch Health, Canada Inc.

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-11-08

Date Granted : 2016-11-01

Bupropion Hydrochloride, Naltrexone Hydrochloride

Brand Name : CONTRAVE

Patent Number : 2668884

Filing Date : 2007-11-08

Strength per Unit : 8mg / 90mg

Dosage Form : TABLET (EXTENDED-RELEASE)

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-11-08

Date Granted : 2016-11-01

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Bausch Health, Canada Inc.

Bupropion Hydrochloride, Naltrexone Hydrochloride

Peptide Process CMC

Not Confirmed

Bausch Health, Canada Inc.

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-11-08

Date Granted : 2016-08-02

Bupropion Hydrochloride, Naltrexone Hydrochloride

Brand Name : CONTRAVE

Patent Number : 2668885

Filing Date : 2007-11-08

Strength per Unit : 8mg / 90mg

Dosage Form : TABLET (EXTENDED-RELEASE)

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-11-08

Date Granted : 2016-08-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Bausch Health, Canada Inc.

Bupropion Hydrochloride, Naltrexone Hydrochloride

Peptide Process CMC

Not Confirmed

Bausch Health, Canada Inc.

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-12-04

Date Granted : 2023-05-02

Bupropion Hydrochloride, Naltrexone Hydrochloride

Brand Name : CONTRAVE

Patent Number : 2932127

Filing Date : 2014-12-04

Strength per Unit : 8mg / 90mg

Dosage Form : TABLET (EXTENDED-RELEASE)

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-12-04

Date Granted : 2023-05-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!